07:00 , Jun 15, 2015 |  BC Week In Review  |  Company News

Novo Nordisk, J&J, Innate Pharma deal

Johnson & Johnson’s Janssen Biotech Inc. unit received an exclusive, worldwide license from Novo Nordisk to develop and commercialize anti-NKG2D ( NN8555) for autoimmune indications. Last year, Novo discontinued R&D within inflammatory disorders, including...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Clinical News

Anti-NKG2D: Phase II planned

Novo Nordisk disclosed in its 2013 earnings that it plans to resume Phase II testing of NN8555 to treat CD. The company could not be reached for details. In 2012, Novo Nordisk discontinued development of...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

Anti-NKG2D: Development discontinued

Novo Nordisk discontinued development of anti-NKG2D to treat CD after an interim futility analysis of 74 patients in a double-blind, placebo-controlled Phase IIa trial showed that the compound did not meet the pre-specified criteria for...
08:00 , Dec 24, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) was off $0.43 to $5.79 on Friday after FDA approved an NDA for Adasuve Staccato loxapine to treat acute agitation in adults with schizophrenia or bipolar disorder with a boxed...
01:32 , Dec 20, 2012 |  BC Extra  |  Clinical News

Victoza/Tresiba combo meets diabetes endpoint

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said IDegLira plus metformin met the primary endpoint of reducing HbA1c from baseline to week 26 vs. Tresiba plus metformin in the Phase IIIa DUAL II trial to treat Type...
07:00 , Sep 20, 2012 |  BC Innovations  |  Tools & Techniques

Strategic synergy

Researchers from the New York University School of Medicine have shown that induction of NKG2D ligands on poorly immunogenic tumor cells is a key molecular mechanism that contributes to the synergy of radiotherapy plus anti-CTLA-4...
07:00 , Sep 20, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Killer cell lectin-like receptor subfamily K member 1 (KLRK1; CD314; NKG2D) ligands as markers to predict response to anti-CTLA-4 (CD152) therapies...
08:00 , Nov 8, 2010 |  BC Week In Review  |  Clinical News

Anti-NKG2D: Phase IIa started

In August, Novo Nordisk began the double-blind, placebo-controlled, German Phase IIa Study NN8555-3796 trial to evaluate 4 mg/kg subcutaneous anti-NKG2D in 54 patients. In 2008, Novo Nordisk gained rights to the mAb from Innate...
07:00 , May 11, 2009 |  BC Week In Review  |  Company News

Innate Pharma, Novo Nordisk deal

Innate disclosed in its 1Q09 earnings that the R&D portion of a 2003 deal granting Novo rights to receptor targets expressed by natural killer (NK) cells expired in March. License rights to the compounds developed...
08:00 , Nov 20, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation ...